Scandion Oncology A/S (SCOL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scandion Oncology A/S (SCOL) has a cash flow conversion efficiency ratio of -0.220x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.82 Million ≈ $-195.65K USD) by net assets (Skr8.27 Million ≈ $889.77K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Scandion Oncology A/S to measure how many days the company can operate on defensive assets alone.
Scandion Oncology A/S - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Scandion Oncology A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scandion Oncology A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scandion Oncology A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kiliaro AB
ST:KILI
|
2.808x |
|
ECORUB AB B
F:7M8
|
-0.705x |
|
Transense Technologies PLC
LSE:TRT
|
0.056x |
|
Blackbird PLC
LSE:BIRD
|
-0.118x |
|
Mobilityone Ltd
LSE:MBO
|
0.906x |
|
Gresham House Renewable Energy VCT 1 plc
LSE:GV1O
|
0.003x |
|
LPA Group
LSE:LPA
|
-0.068x |
|
BOOSH PLANT-BASED BRANDS
F:77I
|
N/A |
Annual Cash Flow Conversion Efficiency for Scandion Oncology A/S (2017–2024)
The table below shows the annual cash flow conversion efficiency of Scandion Oncology A/S from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see SCOL market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr8.27 Million ≈ $889.77K |
Skr-27.52 Million ≈ $-2.96 Million |
-3.328x | -104.45% |
| 2023-12-31 | Skr31.12 Million ≈ $3.35 Million |
Skr-50.67 Million ≈ $-5.45 Million |
-1.628x | -64.88% |
| 2022-12-31 | Skr70.33 Million ≈ $7.57 Million |
Skr-69.44 Million ≈ $-7.47 Million |
-0.987x | -107.29% |
| 2021-12-31 | Skr104.54 Million ≈ $11.25 Million |
Skr-49.80 Million ≈ $-5.36 Million |
-0.476x | -325.45% |
| 2020-12-31 | Skr155.87 Million ≈ $16.77 Million |
Skr-17.45 Million ≈ $-1.88 Million |
-0.112x | +79.38% |
| 2019-12-31 | Skr18.34 Million ≈ $1.97 Million |
Skr-9.96 Million ≈ $-1.07 Million |
-0.543x | +48.59% |
| 2018-12-31 | Skr12.57 Million ≈ $1.35 Million |
Skr-13.28 Million ≈ $-1.43 Million |
-1.056x | -28.93% |
| 2017-12-31 | Skr1.45 Million ≈ $156.34K |
Skr-1.19 Million ≈ $-128.07K |
-0.819x | -- |
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more